Elicera Therapeutics announces participation in several industry and partnering conferences
Gothenburg, August 12, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced, that the company will attend the following industry and partnering meetings in 2022:
- Cell Therapy Durability Response Summit
August 22-23, 2022 – Boston, USA
Elicera is sponsoring this event focusing on engineering strategies to deliver persistent, efficacious, safe cell therapy products. Senior Scientist, Tina Sarén, to present the iTANK-platform on August 22 at 1:50 pm EDT and participate in a panel discussion.
https://celltherapydurability.com
- Nordic Life Science Days 2022
September 28-29, 2022 – Malmö, Sweden
- BIO-EUROPE
October 24-26 - Leipzig, Germany
https://informaconnect.com/bioeurope/
- Onco Cell Therapy Summit Europe 2022
November 2-3, Amsterdam, The Netherlands
Elicera is sponsoring this event focusing on engineering strategies to delivering safe and effective adoptive cell therapy products to clinical promise, commercial scale manufacturing and patients. CEO, Jamal El-Mosleh, to present the iTANK-platform on November 2 at 15:55 CET.
https://octseu.com/events/octs-eu
- 7th Annual Oncolytic Virotherapy Summit
December 6-8, 2022 – Boston, USA
Head of translational research at Elicera, Di Yu, to present the iTANK-platform and ELC-201 on December 7 at 9:00 am EDT.
https://oncolytic-virotherapy-summit.com
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About the iTANK platform
The iTANK- (immunoTherapies Activated with NAP for efficient Killing) technology platform has been developed for arming and enhancing CAR T-cells in order to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5)can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK-platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.
For more information, please visit www.elicera.com